# Ganesh Kaundinya

> Ganesh Kaundinya is President and CEO of GlycoEra, a Swiss-US biotech building extracellular protein degraders to treat autoimmune disease. An MIT-trained chemical engineer, he co-founded Momenta Pharmaceuticals and helped grow it from a sugar-sequencing concept into a public company with FDA-approved products, later acquired by Johnson & Johnson for $6.5 billion. At GlycoEra he raised an oversubscribed $130 million Series B in 2025 to push a precision IgG4 degrader toward the clinic.

- **Role:** President and CEO at GlycoEra AG
- **Organizations:** GlycoEra AG, Momenta Pharmaceuticals, Massachusetts Institute of Technology
- **Nationality:** American
- **Education:** Ph.D. in Chemical Engineering, Massachusetts Institute of Technology, M.S. in Chemical Engineering, Massachusetts Institute of Technology
- **Known for:** Co-founded Momenta Pharmaceuticals and built it from a technology concept into a multi-billion-dollar publicly traded company with three FDA-approved commercial products, Led the science behind M-Enoxaparin, the first interchangeable generic low molecular weight heparin approved in the United States (generic of Sanofi-Aventis' Lovenox), Momenta acquired by Johnson & Johnson for $6.5 billion in 2020

## Career timeline

- **1990s-2000s** — Research faculty at MIT; Director, Bioinformatics for the Consortium for Functional Glycomics, an NIH initiative studying complex sugars
- **2001** — Co-founded Momenta Pharmaceuticals out of MIT glycomics research
- **2007** — Became Chief Scientific Officer of Momenta Pharmaceuticals
- **2010** — Science he led delivered FDA approval of M-Enoxaparin, the first interchangeable generic low molecular weight heparin in the US
- **2017** — Promoted to Chief Operating Officer of Momenta, alongside CSO role
- **2020** — Momenta acquired by Johnson & Johnson for $6.5 billion; GlycoEra founded, Kaundinya joins board
- **2022** — Appointed President and CEO of GlycoEra AG
- **2025** — Closed oversubscribed $130 million Series B led by Novo Holdings

## Achievements

- Co-founded Momenta Pharmaceuticals and built it from a technology concept into a multi-billion-dollar publicly traded company with three FDA-approved commercial products
- Led the science behind M-Enoxaparin, the first interchangeable generic low molecular weight heparin approved in the United States (generic of Sanofi-Aventis' Lovenox)
- Momenta acquired by Johnson & Johnson for $6.5 billion in 2020
- Raised over $49 million in Series A capital for GlycoEra as a board member
- Closed an oversubscribed $130 million Series B for GlycoEra in 2025
- Director of Bioinformatics for the NIH Consortium for Functional Glycomics at MIT
- Co-invented novel sequencing technology for complex sugars with Dr. Robert Langer's lab at MIT

## Latest updates

- **2025-05** — GlycoEra closed an oversubscribed $130 million Series B led by Novo Holdings to advance its lead IgG4-targeted protein degrader through clinical data and bring a second program to the clinic.
- **2022-05** — Appointed President and CEO of GlycoEra AG after serving on the board since the company's 2020 inception.

## Links

- Website: https://glycoera.com
- LinkedIn: http://www.linkedin.com/in/gvkaundinya
- Twitter/X: https://twitter.com/glycoera

---

Profile page: https://yespress.io/ganesh-kaundinya
Published by YesPress — https://yespress.io
Last updated: 2026-06-04